Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04434092 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT04434092 · ClinicalTrials.gov record · last posted 2026-08-18

A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors

Name: A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors — clinical trial record (NCT04434092)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: COMMODORE 2

StatusActive, Not Recruiting

PhasePhase 3

SponsorHoffmann-La Roche

Started2020-10-08

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

A study designed to evaluate the non-inferiority of crovalimab compared with eculizumab in participants with PNH who have not been previously treated with complement inhibitor therapy.

Protocol amendment history 1 change detected by DataLookout

2026-08-19

Completion moved earlier: 2027-09-30 → 2027-04-18

Trial Details

NCT Number	NCT04434092
Lead Sponsor	Hoffmann-La Roche Collaborators: Chugai Pharmaceutical
Conditions	Paroxysmal Nocturnal Hemoglobinuria
Enrollment	210 participants
Start Date	2020-10-08
Primary Completion	2022-11-16 (estimated)
Study Completion	2027-04-18 (estimated)
Updated on ClinicalTrials.gov	2026-08-18